A. Aha, HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines, Circulation, vol.123, pp.269-367, 2011.

J. Eikelboom, S. Connolly, and M. Brueckmann, Dabigatran versus Warfarin in Patients with Mechanical Heart Valves, New England Journal of Medicine, vol.369, issue.13, pp.1206-1220, 2013.
DOI : 10.1056/NEJMoa1300615

C. Miller, S. Grandi, A. Shimony, K. Filion, and M. Eisenberg, Meta-Analysis of Efficacy and Safety of New Oral Anticoagulants (Dabigatran, Rivaroxaban, Apixaban) Versus Warfarin in Patients With Atrial Fibrillation, The American Journal of Cardiology, vol.110, issue.3
DOI : 10.1016/j.amjcard.2012.03.049

A. Elias and J. Fiessinger, Maladie thrombo-embolique veineuse, pp.122-125, 1995.

A. Lee, M. Levine, and R. Baker, Low-Molecular-Weight Heparin versus a Coumarin for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer, New England Journal of Medicine, vol.349, issue.2, pp.146-53, 2003.
DOI : 10.1056/NEJMoa025313

V. Siguret, I. Gouin, and M. Debray, Initiation of warfarin therapy in elderly medical inpatients: A safe and accurate regimen, The American Journal of Medicine, vol.118, issue.2, pp.137-179, 2005.
DOI : 10.1016/j.amjmed.2004.07.053

C. Moreau, E. Pautas, and I. Gouin-thibault, Predicting the warfarin maintenance dose in elderly inpatients at treatment initiation: accuracy of dosing algorithms incorporating or not VKORC1/CYP2C9 genotypes, Journal of Thrombosis and Haemostasis, vol.55, issue.4, pp.711-719, 2011.
DOI : 10.1111/j.1538-7836.2011.04213.x

D. Budnitz, M. Lovegrove, N. Shehab, and C. Richards, Emergency Hospitalizations for Adverse Drug Events in Older Americans, New England Journal of Medicine, vol.365, issue.21, pp.2002-2014, 2011.
DOI : 10.1056/NEJMsa1103053

P. Sie, J. Bouget, and T. Boulain, Prise en charge des surdosages en antivitamine K, des situations à risque hémorragique chez les patients traités par antivitamine K en ville et en milieu hospitalier, J Mal Vasc, vol.33, pp.202-215, 2008.

J. Healey, J. Eikelboom, and J. Douketis, Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin: Results From the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial, Circulation, vol.126, issue.3, pp.343-351, 2012.
DOI : 10.1161/CIRCULATIONAHA.111.090464

M. Patel, K. Mahaffey, and J. Garg, Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation, New England Journal of Medicine, vol.365, issue.10, pp.883-91, 2011.
DOI : 10.1056/NEJMoa1009638
URL : https://hal.archives-ouvertes.fr/hal-01038111

F. Schiele, J. Van-ryn, and K. Canada, A specific antidote for dabigatran: functional and structural characterization, Blood, vol.121, issue.18, pp.3554-62, 2013.
DOI : 10.1182/blood-2012-11-468207

G. Lu, F. Deguzman, and S. Hollenbach, A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa, Nature Medicine, vol.48, issue.4, pp.446-51, 2013.
DOI : 10.1038/nm.3102

T. Singh, T. Maw, and B. Henry, Extracorporeal Therapy for Dabigatran Removal in the Treatment of Acute Bleeding: A Single Center Experience, Clinical Journal of the American Society of Nephrology, vol.8, issue.9, pp.1533-1542, 2013.
DOI : 10.2215/CJN.01570213

W. Zhou, S. Schwarting, and S. Illanes, Hemostatic Therapy in Experimental Intracerebral Hemorrhage Associated With the Direct Thrombin Inhibitor Dabigatran, Stroke, vol.42, issue.12, pp.3594-3603, 2011.
DOI : 10.1161/STROKEAHA.111.624650